C
Cingulate Inc. (CING)
NCM – Real Time Price. Currency in USD
5.11
-0.10 (-1.83%)
Market open: Aug 12, 2026, 11:58 AM EDT
5.12
-0.08 (-1.54%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
5.11
-0.10 (-1.83%)
Market open: Aug 12, 2026, 11:58 AM EDT
5.12
-0.08 (-1.54%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
| Name | Position |
|---|---|
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive VP & Chief Medical Officer |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive VP & Chief Science Officer |
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, CEO & Chairman of the Board |
| Mr. Downey Bryan Wade | Executive VP & Chief Commercial Officer |
| Mr. Thomas Dalton | Vice President of Investor & Public Relations |
| Ms. Jennifer L. Callahan CPA | Executive VP, CFO & Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-07-23 | 8-K | form8-k.htm |
| 2026-07-15 | S-8 | forms-8.htm |
| 2026-07-14 | 8-K | form8-k.htm |
| 2026-07-02 | 8-K | form8-k.htm |
| 2026-06-16 | 8-K | form8-k.htm |
| 2026-06-02 | 8-K | form8-k.htm |
| 2026-05-29 | DEFA14A | formdefa14a.htm |
| 2026-05-29 | DEF 14A | formdef14a.htm |
| 2026-05-29 | ARS | formars.pdf |
| 2026-05-19 | 8-K | form8-k.htm |